Alzai Health (FRA:H2F) Change In Receivables: €-0.05 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H2F Alzai Health Corp FRA:H2F
9 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is Alzai Health Change In Receivables?

Alzai Health FRA:H2F -1.62% 9 Change In Receivables is €-0.05 Mil as of Jan. 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Alzai Health's change in receivables for the quarter that ended in Jan. 2026 was €-0.05 Mil. It means Alzai Health's Accounts Receivable increased by €0.05 Mil from Oct. 2025 to Jan. 2026 .

Alzai Health's change in receivables for the fiscal year that ended in Apr. 2025 was €0.00 Mil. It means Alzai Health's Accounts Receivable stayed the same from . 20 to Apr. 2025 .

Alzai Health's Accounts Receivable for the quarter that ended in Jan. 2026 was €0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alzai Health's Days Sales Outstanding for the three months ended in Jan. 2026 was 354.26.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alzai Health's liquidation value for the three months ended in Jan. 2026 was €-0.49 Mil.

Alzai Health  (FRA:H2F) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alzai Health's Days Sales Outstanding for the quarter that ended in Jan. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.066/0.017*91
=354.26

2. In Ben Graham's calculation of liquidation value, Alzai Health's accounts receivable are only considered to be worth 75% of book value:

Alzai Health's liquidation value for the quarter that ended in Jan. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.476-1.018+0.75 * 0.066+0.5 * 0
=-0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health Change In Receivables Related Terms

Alzai Health Change In Receivables Historical Data

* Premium members only.

The historical data trend for Alzai Health's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health Change In Receivables Chart

Alzai Health Annual Data
Trend Apr25
Change In Receivables
0.00

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
Change In Receivables -0.02 0.01 -0.00 -0.01 -0.05
FRA:H2F
9GF Score
Alzai Health Corp FRA:H2F
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-0.05 Mil mean?
Alzai Health (FRA:H2F) has a Change In Receivables of €-0.05 Mil as of Jan. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Alzai Health and its competitors.
Is Alzai Health's Change In Receivables too high?
Alzai Health's current Change In Receivables is €-0.05 Mil. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's Change In Receivables compare to VRTX and REGN?
Alzai Health's Change In Receivables of €-0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Alzai Health and its competitors. Alzai Health's current Change In Receivables is €-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current Change In Receivables of €-0.05 Mil. The current Change In Receivables is €-0.05 Mil. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current Change In Receivables is €-0.05 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Other Exchanges ALZI:Canada
Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for FRA:H2F

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price